As the most common bone disease in
|
|
- Poppy Gibson
- 5 years ago
- Views:
Transcription
1 AN UPDATE ON OSTEOPOROSIS EPIDEMIOLOGY AND BONE PHYSIOLOGY Elena M. Umland, PharmD* ABSTRACT Osteoporosis is a significant public health concern, affecting 10 million Americans over the age of 50 and causing fractures in 1.5 million patients annually. Although achievement of peak bone mass has always been considered of extreme importance, bone mineral density (BMD) alone does not predict fracture risk, and as such, experts recommend using a fracture prediction algorithm that takes into account femoral neck BMD and identified clinical risk factors. This article focuses on the epidemiology and pathophysiology of osteoporosis, with a discussion on the role of the endocrine system and the receptor activator of nuclear factor-κb (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) pathway in bone remodeling. RANK/RANKL/OPG is a signal transduction pathway that appears to be the molecular mechanism by which osteoblasts and osteoclasts function in a coordinated fashion at the basic multicellular unit. Endocrine components that are discussed as having a skeletal influence include estrogen, parathyroid hormone, growth hormone, insulin-like growth factor-1, thyroid hormone, and cortisol. (Adv Stud Pharm. 2008;5(7): ) *Associate Dean for Academic Affairs, Jefferson College of Health Professions, Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania. Address correspondence to: Elena M. Umland, PharmD, Associate Dean for Academic Affairs, Jefferson College of Health Professions, Jefferson School of Pharmacy, Thomas Jefferson University, 130 South 9th Street, Philadelphia, PA Elena.umland@jefferson.edu. As the most common bone disease in humans, osteoporosis is steadily increasing in prevalence due to a growing elderly population and, thus, represents a major public health concern. 1 This skeletal disorder is characterized by several pathologic events (ie, low bone mass, deterioration of bone tissue, disruption of bone architecture, and reduced bone strength), all of which increase the risk for fractures. 1,2 Based on the World Health Organization (WHO) diagnostic criteria, o s t e o p o rosis is defined by bone mineral density (BMD) at the hip or spine that is less than or equal to 2.5 standard deviations (SDs) below the young normal mean reference population (T-score). 1 Dual-energy X- ray absorptiometry (DXA) at the spine or hip is the gold-standard test for measuring central BMD (see Table 1 for T-scores corresponding to various levels of bone health). 1,2 A decrease of 1 SD correlates to an approximate 10% to 12% decrease in BMD and an increase in fracture risk by a factor of 1.5 to For every 1 SD decline in spine BMD, the risk of spine fracture increases 2.3-fold and the risk of hip fracture increases 2.6-fold. 2 EPIDEMIOLOGY Based on the 2004 Surgeon General s report, an estimated 10 million Americans over the age of 50 have osteoporosis of the hip, 34 million have osteopenia, and 1.5 million suffer from an osteoporosis-related fracture annually. 3 These statistics contribute to more than hospitalizations, over emergency department visits, more than 2.6 million physician visits, and the placement of patients into nursing homes annually in the United States. 3 Fractures, most commonly those of the vertebrae (spine), proximal femur (hip), and distal forearm (wrist), are the most relevant clinical sequelae of osteoporosis. 1 Complications of fractures, particularly in the 210 Vol. 5, No. 7 October 2008
2 Table 1. T-Score and the Definition of Bone Health Normal bone mineral density T-score at or above -1 Osteopenia T-score of -1.1 to -2.4 Osteoporosis T-score at or below -2.5 Reprinted with permission from Menopause. 2006;13: elderly, include increased mortality (with hip and vertebral fractures) and morbidity, which manifests as significant pain, loss of ability to perform activities of daily living or to ambulate, and an increased risk of developing pressure sores, pneumonia, and urinary tract infections. Osteoporosis and its resultant fractures may also contribute to the development of a negative body image, reduced self-esteem, and declining mood. 3 Fracture-related statistics are quire alarming, with the total lifetime risk for sustaining a fracture of the hip, spine, or wrist being approximately 40% for women and 13% for men. 4 Worldwide, there was an estimated 1.66 million hip fractures in As a result of the increasing number of elderly patients, the Surgeon General estimates that the number of hip fractures and their associated costs may increase by 50% in 2025 and may double or triple by the year 2040, with the number of hip fractures potentially reaching 6.3 million by the year ,5 Hip fractures occur, on average, at age 82 and are generally associated with a 10% to 20% increase in mortality (especially in the elderly), as well as recurrence, within the first year. 3 Up to 25% of patents with hip fractures may require long-term care, and only 40% fully regain their prefracture level of independence. 1 Although osteoporosis is often viewed as a disease affecting women, it is also known to significantly affect men. Using male-specific cutoffs, 6% of US men over 50 years of age have osteoporosis and 47% have osteopenia, versus 18% and 50% of women, respectively. 6 Almost 50% of all hip fractures in men occur before the age of 80, and 33% of worldwide hip fractures occur in men. 6 Furthermore, although more women than men are affected by this disease, more men than women are actually known to die in the year following a hip fracture. From an economic perspective, the direct costs associated with fractures ranged from $12.2 to $17.9 billion in 2002, with indirect costs likely adding billions of dollars to this figure. 3 In a recent 2008 publication focusing on the epidemiology of osteoporosis, the combined annual costs of all osteoporosis-related fractures in the United States was estimated to be $20 billion. 5 Overall, hip fractures account for approximately 72% of these fracture-related costs. 1 GENERAL BONE HEALTH AND RISK FACTORS The foundation of optimal bone health lies in attaining the greatest peak bone mass possible. Ac h i e ved by the age of 25 to 30 years, peak bone mass is determined largely by genetic factors, although other impacting factors (ie, nutrition, endocrine status, physical activity, and health during growth) also play a ro l e. 4 For all patients, both young and old, the recommendations for achieving and maintaining optimal bone health include receiving the appro p r i a t e amount of calcium and vitamin D, performing re g u- lar weight-bearing exe rcise, avoiding or minimizing alcohol use, and being aware of, and employing, fall p re vention strategies. And although achieving peak bone mass is of e x t rem e importance, BMD alone does not pre d i c t f r a c t u re risk, as evidenced by data showing that fract u res still occur in the absence of W H O - d e f i n e d o s t e o p o ro s i s. 4 Of women aged 65 or older, 40% of those with hip fractures have osteopenia (not osteop o rosis), and 74% of those with nonve rtebral fract u res have T- s c o res that are higher than the cutoff values for defining osteoporosis (greater than -2.5). 4 In one study, re s e a rchers observed that of patients with normal T- s c o res, 16.1% had evidence of a prior ve rtebral fracture, and of those, 26.3% had multiple prior fracture s. 5 These data are further supported by the W H O, which has stated that DXA, by itself, is not optimal for detecting patients at high risk for fractures. DXA is considered to have high specificity; meaning that the risk of fracture is high when osteoporosis by T- s c o re definition is present. Howe ve r, DXA possesses l ow sensitivity; meaning that fracture risk is not, nece s s a r i l y, negligible when BMD is normal. 7 T h e re f o re, in response to the growing body of evidence indicating that BMD alone is not sufficient in determining f r a c t u re risk, the WHO has developed an algorithm that takes into account femoral neck BMD and specific clinical risk factors (Table 2) to identify an indiv i d u a l s 10-year probability of a hip fracture and any University of Tennessee Advanced Studies in Pharmacy 211
3 Table 2. Risk Factors Assessed in Determining F r a c t u re Risk Femoral neck bone mineral density Prior fragility fracture Glucocorticoid exposure Age Parental history of (hip) fracture Smoking Excessive intake of alcohol Rheumatoid arthritis Low body mass index Data from World Health Organization. 7 other major osteoporotic fracture (see article by Christina Barrington, PharmD, for more information on the WHO fracture risk algorithm). 1, 7 In general, it is imperative that conditions and medications contributing to osteoporosis (Tables 3 and 4) and risk factors employed in estimating fracture risk (Table 2) be observe d. 1, 8 THE BONE REMODELING PROCESS Along with availability of evidence-based tools that s u p p o rt healthcare providers in making more informed decisions re g a rding osteoporosis management, re s e a rc h p roviding greater insight into the process of bone remodeling has increased substantially. Overall, bone remodeling replaces approximately 5% to 10% of the adult human skeleton annually, and aids in the maintenance of a healthy skeleton by continually removing older bone and replacing it with newer bone. 1,9 Osteoblasts (cells responsible for bone formation) and osteoclasts (cells responsible for bone resorption or the breakdown of bone) compose the basic multicellular unit (BMU), which is where bone remodeling and reconstruction occur. 10 Within each BMU, the process of bone resorption takes approximately 3 weeks (per site), whereas bone remodeling and refilling of lost bone may take up to 3 to 4 m o n t h s. 9 Osteocytes, cells derived from senescent osteoblasts, direct when and where bone remodeling will occur. 10 Imbalances in this normal remodeling process (as a result of menopause and conditions noted in Table 3) lead to greater bone removal than replacement, and subsequently to a reduction in BMD, the Table 3. Common Conditions Associated with S e c o n d a ry Osteoporosis Condition Anorexia nervosa Diabetes mellitus type 1 Malignancy Organ transplantation Rheumatoid arthritis Chronic obstructive pulmonary disease Chronic renal disease Cause or Mechanism Malnutrition, amenorrhea (estrogen deficiency), or excess endogenous cortisol Decreased bone formation, impaired IGF-1, excessive renal calcium loss, or secondary hyperparathyroidism Aggressive chemotherapy, long-term highdose glucocorticoid treatment, irradiation, poor nutrition, or underlying illness (may affect bone-cell function) Chemotherapy, glucocorticoid use, or immunosuppressive therapy Glucocorticoid therapy or decreased mobility Reduced lung function, smoking, glucocorticoid use, low BMI, or immobility due to dyspnea Impaired vitamin D hydroxylation or secondary hyperparathyroidism BMI = body mass index; IGF = insulin-like growth factor. Data from Hansen and Vondracek. 8 Table 4. Medications Associated with Osteoporo s i s Medication(s) or Treatment Cause or Mechanism Anticonvulsants Cyclosporine Glucocorticoid use (long-term) Stimulation of bone resorption and sup- pression of osteoblast function Heparin (high dosage and long duration) Irradiation Methotrexate Tacrolimus Thyroid hormone Warfarin Increased bone turnover, increased metabolism and clearance of vitamin D, hypocalcemia, or hypophosphatemia Increased bone turnover and bone loss in animals Impaired bone formation, increased bone resorption, decreased calcium absorption, increased calcium excretion, or oral and possibly inhaled glucocorticoids Direct detrimental effects on bone or pituitary hormone deficiencies from cranial irradiation Dose-dependent bone loss or increase in bone resorption and inhibition of bone formation Increased bone loss in animals Increased bone turnover and resorption Low vitamin K level leading to impaired bone formation* *Mechanism is controversial. Reprinted with permission from Hansen and Vondracek. Am J Health Syst Pharm. 2004;61: Vol. 5, No. 7 October 2008
4 development of osteoporosis and, ultimately, fractures. 1 Many neighboring organ systems, associated hormones, and underlying molecular processes contribute to normal bone remodeling and pathophysiologic skeletal alterations. RANK/RANKL/OPG PATHWAY This signal transduction pathway appears to be the molecular mechanism by which osteoblasts and osteoclasts function in a coordinated fashion at the BMU. 10 Receptor activator of nuclear factor-κb (RANK) is a type I homotrimeric transmembrane protein that is e x p ressed widely on normal cells and on the surface of osteoclasts and osteoclast pre c u r s o r s. 10 Ac t i va t i n g mutations of RANK has resulted in increased osteoclast formation and activity. 11 RANK ligand (RANKL) is a type II homotrimeric transmembrane p rotein that is synthesized by osteoblasts, bone marrow stromal cells, and activated T cells. 10, 12 Ex p re s s e d both as a membrane-bound and a secreted pro t e i n, RANKL stimulates the release of immature osteoclast p rogenitors into the circulation and binds to osteop rotegerin (OPG), a soluble decoy re c e p t o r. 10, 11 T h e binding of RANKL to RANK results in differe n t i a- tion of osteoclast precursors into mature, functional osteoclasts, in addition to direct activation of alre a d y m a t u re osteoclasts. 10 Osteoprotegerin, a soluble member of the tumor necrosis factor (TNF) receptor family, is expressed on osteoblasts and in bone marrow (among many other tissues), and is a very effective inhibitor of osteoclast formation. 9,11 The OPG protein, however, is unstable and difficult to obtain because it undergoes rapid degradation in vivo. 12 The binding of RANKL to the decoy receptor OPG avoids RANK-RANKL interaction and, therefore, inhibits resorption, because the differentiation of osteoclast precursors into mature osteoclasts and direct activation of mature osteoclasts are not prompted to occur. Thus essentially, blockade of the RANK/RANKL signal pathway leads to inhibition in the formation and differentiation of osteoclasts, and the resultant bone resorption process that follows. 12 Osteoblast expression of RANKL and OPG influences bone resorption and, generally, upregulation of RANKL expression by cytokines and growth factors is associated with relative downregulation of OPG (see article by Mary Beth O Connell, PharmD, BCPS, FASHP, FCCP, on therapeutic applicability of the RANK/RANKL/OPG pathway). 11 ENDOCRINE INFLUENCES The sex hormones estrogen and testostero n e, which are vital in regulating skeletal growth and maintaining bone mass and strength, have effects in both men and women. Testosterone has direct anabolic effects on bone and is a source of estrogen, because it is converted to estrogen in fat cells. 3 Functional estrogen receptors are expressed on osteoblasts, osteoclasts, and osteocytes. 10 These receptors are also expressed on bone marrow stromal cells, which provide physical support for future osteoclasts, T cells, B cells, and many other bone marrow cells. 10 Estrogen deficiency causes T cells to release a variety of inflammatory cytokines that have various actions. For example, interleukin (IL)-1, IL-6, and TNF-α promote osteoclast recruitment, differentiation, and prolonged survival. IL-7 inhibits osteoblast differentiation and activity, causing apoptosis of osteoblasts. Menopausal estrogen decline leads to a large, sudden, increase in the osteoclast population and pro l o n- gation of their life span. 13 And because estro g e n lengthens the working lives of osetoblasts by suppre s s- ing cell apoptosis, a drop in estrogen also results in loss of osteoblast pro d u c t i v i t y. 13 In addition, nongenomic e s t rogen receptors on the surface of intestinal epithelial cells help drive calcium into the cells, thus a decline in e s t rogen may reduce intestinal calcium uptake. 13 Pa r a t h y roid hormone (PTH) acts on the kidney to c o n s e rve calcium and to stimulate calcitriol pro d u c t i o n, which increases intestinal absorption of calcium. 3 P T H also acts on the skeleton to increase movement of calcium from blood to bone. PTH-activated re c e p t o r s reduce osteoblast apoptosis when stimulated, leading to an increase in the working lives of osteoblasts and subs e q u e n t l y, to increased bone formation. 13 PTH also has i n d i rect anabolic effects through regulation of other bone-forming skeletal growth factors (eg, insulin-like g rowth factor-1 [IGF-1]) and growth factor antagonists (eg, sclero s t i n ). 14 PTH levels begin to decline when the c i rculating form of vitamin D falls below 30 ng/ml. 10 Other endocrine hormones that influence the skeleton include growth hormone (GH), thyroid hormone (TH), and cortisol. De r i ved from the pituitary gland, GH accelerates skeletal growth at puberty and stimulates production of IGF-1, which exe rts direct action on osteoblasts and is necessary for skeletal deve l o p m e n t and maintenance of bone mass. 3, 14 De c reased pro d u c- tion of GH and IGF-1 with advancing age may be partially responsible for the impaired ability of older University of Tennessee Advanced Studies in Pharmacy 213
5 individuals to form bone or to replace lost bone. 3 T H i n c reases the energy-carrying capacity of all cells (including bone cells), and there f o re, it increases the rate of bone formation and resorption. W h e reas TH deficiency can impair growth in children, TH excess may incre a s e bone resorption, weakening the skeleton. 3 C o rtisol, the major hormone of the adrenal gland, has complex effects on the skeleton, with small amounts being necessary for normal bone development and exc e s s i ve amounts blocking bone growth. To this point, long-term use of glucoc o rticoids decreases bone formation and increases bone resorption, and is there f o re, considered a major contributor to secondary osteoporo s i s. 3 GENETIC FACTORS Also a significant influence on bone remodeling, genetic variants may impact bone strength. Sequence variants that are significantly associated with BMD have been identified in 5 genomic regions; 3 of these regions are close to or within: (1) the RANKL gene ( c h romosomal location, 13 q14); (2) OPG gene (8q24); and (3) the estrogen receptor-1 gene (6q25). 15 These 3 chromosomal locations appear to influence BMD at both the spine and hip. When tested for associations between low-trauma fracture and the singlenucleotide polymorphisms associated with BMD, the 8q24 locus was associated with all categories of fractures and the 18q21 locus (RANK) was associated with low-trauma fractures. 15 CONCLUSIONS Many physiologic factors are responsible for maintaining a healthy skeleton, as well as contributing to pathologic bone states, such as osteoporo s i s. An understanding of the normal bone re m o d e l i n g p rocess and the various factors that may affect the balance between bone formation and bone resorption is critical to the optimal management of osteoporo s i s. REFERENCES 1. National Osteoporosis Foundation. Clinician s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006;13: US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; Lane JM, Serota AC, Raphael B. Osteoporosis: differences and similarities in male and female patients. Orthop Clin North Am. 2006;37: Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. Curr Rheumatol Rep. 2008;10: Ebeling PR. Osteoporosis in men. N Engl J Med. 2008;358: World Health Organization. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Level. Geneva, Switzerland: WHO Press, World Health Organization; Hansen LB, Vondracek SF. Prevention and treatment of nonpostmenopausal osteoporosis. Am J Health Syst Pharm. 2004;61: Martin TJ, Seeman E. New mechanisms and targets in the treatment of bone fragility. Clin Sci. 2007;112: Becker C. Pathophysiology and clinical manifestations of osteoporosis. Clin Cornerstone. 2006;8: Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep. 2007;5: Bai Y, Yang F, Xuan K, et al. Inhibition of RANK/RANKL signal transduction pathway: a promising approach for osteoporosis treatment. Med Hypotheses. In press. 13. Whitfield JF, Morley P, Willick GE. The parathyroid hormones: bone-forming agents for treatment of osteoporosis. Med Gen Med. 2000;2(4). [Formerly published in Medscape Women s Health ejournal 5(5),2000]. Available at: Accessed August 28, Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med. 2007;357: Styrkarsdottir U, Halldorsson BV, Gretarasdottir S, et al. Multiple genetic loci for bone mineral density and fractures. N Engl J Med. 2008;358: Vol. 5, No. 7 October 2008
Skeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationThe Skeletal Response to Aging: There s No Bones About It!
The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationPathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis. March 15, 2016 Bone ECHO Kate T Queen, MD
Pathophysiology of Postmenopausal & Glucocorticoid Induced Osteoporosis March 15, 2016 Bone ECHO Kate T Queen, MD Review: normal bone formation Bone Modeling Remodeling Peak Bone Mass Maximum bone mass
More informationAMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care
AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationOsteoporosis. Treatment of a Silently Developing Disease
Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationOsteoporosis: Risk Factors, Diagnostic Methods And Treatment Options
ISPUB.COM The Internet Journal of Academic Physician Assistants Volume 1 Number 1 Osteoporosis: Risk Factors, Diagnostic Methods And Treatment Options K Ihrke Citation K Ihrke.. The Internet Journal of
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationEndocrine Regulation of Calcium and Phosphate Metabolism
Endocrine Regulation of Calcium and Phosphate Metabolism Huiping Wang ( 王会平 ), PhD Department of Physiology Rm C516, Block C, Research Building, School of Medicine Tel: 88208252 Email: wanghuiping@zju.edu.cn
More informationOsteoporosis, Osteomalasia & rickets. Bone disorders
Osteoporosis, Osteomalasia & rickets Bone disorders Thank You for Your comments Voice--- Ok Lecture too long--- this is in schedule??? More interaction--- I can do that inshalla Slides are crowded--- but
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More informationLOVE YOUR BONES Protect your future
www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women
More informationMetabolic Bone Disease and the Gastroenterologist
VOLUME 8, ISSUE 3, YEAR 2009 Metabolic Bone Disease and the Gastroenterologist Peter R. McNally, DO, FACP, FACG University Colorado at Denver, School of Medicine, Center for Human Simulation Series Introduction:
More informationOsteoporosis in Men Wendy Rosenthal PharmD. This program has been brought to you by PharmCon
Osteoporosis in Men Wendy Rosenthal PharmD This program has been brought to you by PharmCon Osteoporosis in Men Speaker: Dr. Wendy Rosenthal, President of MedOutcomes, will be the presenter for this webcast.
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationNutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio
Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development
More informationAwaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page
f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the
More informationElecsys bone marker panel. Optimal patient management starts in the laboratory
bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic
More informationChapter 39: Exercise prescription in those with osteoporosis
Chapter 39: Exercise prescription in those with osteoporosis American College of Sports Medicine. (2010). ACSM's resource manual for guidelines for exercise testing and prescription (6th ed.). New York:
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationDownload slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis Update. Greg Summers Consultant Rheumatologist
Osteoporosis Update Greg Summers Consultant Rheumatologist DEFINITION OSTEOPOROSIS is LOW BONE MASS (& micro-architectural deterioration) causing AN INCREASED RISK OF FRACTURE 23 years 82 years 23 y/o
More informationCalcium Nephrolithiasis and Bone Health. Noah S. Schenkman, MD
Calcium Nephrolithiasis and Bone Health Noah S. Schenkman, MD Associate Professor of Urology and Residency Program Director, University of Virginia Health System; Charlottesville, Virginia Objectives:
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationBONE HEALTH Dr. Tia Lillie. Exercise, Physical Activity and Osteoporosis
BONE HEALTH Dr. Tia Lillie Exercise, Physical Activity and Osteoporosis Food for thought... How old would you be if you didn t know how old you were? DEFINITION: Osteoporosis Osteoporosis (OP) is a disease
More informationObjectives. Discuss bone health and the consequences of osteoporosis on patients medical and disability status.
Objectives Discuss bone health and the consequences of osteoporosis on patients medical and disability status. Discuss the pathophysiology of osteoporosis and major risk factors. Assess the major diagnostic
More informationNATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES
NATIONAL COALITION FOR OSTEOPOROSIS AND RELATED BONE DISEASES Fact Sheet FY 2007 What is the Mission of the Bone Coalition? The National Coalition for Osteoporosis and Related Bone Diseases is dedicated
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationBone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationTREATMENT OF OSTEOPOROSIS
TREATMENT OF OSTEOPOROSIS Summary Prevention is the key issue in the management of osteoporosis. HRT is the agent of choice for prevention of postmenopausal osteoporosis. Bisphosphonates and Calcitonin
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationHelpful information about bone health & osteoporosis Patient Resource
Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationBONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology
BONE REMODELLING Tim Arnett Department of Anatomy and Developmental Biology University College London The skeleton, out of sight and often out of mind, is a formidable mass of tissue occupying about 9%
More informationSpongeBone Menopants*
SpongeBone Menopants* Adam Fershko, MD, FACP Kettering Health Network *Postmenopausal Osteoporosis Objectives O Epidemiology O Clinical significance O Pathophysiology O Screening and Diagnosis O Treatment
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationJOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014
HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationModélisation par éléments finis des effets des médicaments sur le remodelage osseux : Approche mécanobiologique
Modélisation par éléments finis des effets des médicaments sur le remodelage osseux : Approche mécanobiologique Ridha Hambli Prisme Institute 8, Rue Léonard de Vinci, 45072 Orléans cedex 2, France Phone
More informationThe Bare Bones of Osteoporosis. Wendy Rosenthal, PharmD
The Bare Bones of Osteoporosis Wendy Rosenthal, PharmD Definition A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase
More informationFunctions of the Skeletal System. Chapter 6: Osseous Tissue and Bone Structure. Classification of Bones. Bone Shapes
Chapter 6: Osseous Tissue and Bone Structure Functions of the Skeletal System 1. Support 2. Storage of minerals (calcium) 3. Storage of lipids (yellow marrow) 4. Blood cell production (red marrow) 5. Protection
More informationOverview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence
Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling
More informationWHAT KEEPS OUR BONES STRONG?
WHAT KEEPS OUR BONES STRONG? The role of diet and lifestyle in osteoporosis prevention Thomas Walczyk PhD, Associate Professor Food Science and Technology Programme Department of Chemistry, Faculty of
More informationTo understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.
Nutrition Aspects of Osteoporosis Care and Treatment t Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, OH. Objectives To understand bone growth and development across the lifespan.
More informationS H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women
S H A R E D C A R E G U I D E L I N E Drug: Denosumab 60mg injection Indication: treatment of osteoporosis in postmenopausal women Introduction Indication: Denosumab (Prolia ) is recommended in NICE TA204
More informationAdditional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015. Dr.
Additional Research is Needed to Determine the Effects of Soy Protein on Calcium Binding and Absorption NDFS 435 3/26/2015 Dr. Tessem Osteoporosis is a public health problem in all stages of life. Many
More informationCorrelation between Thyroid Function and Bone Mineral Density in Elderly People
IBBJ Spring 2016, Vol 2, No 2 Original Article Correlation between Thyroid Function and Bone Mineral Density in Elderly People Ali Mirzapour 1, Fatemeh Shahnavazi 2, Ahmad Karkhah 3, Seyed Reza Hosseini
More informationIndex. Rheum Dis Clin N Am 32 (2006) Note: Page numbers of article titles are in boldface type.
Rheum Dis Clin N Am 32 (2006) 775 780 Index Note: Page numbers of article titles are in boldface type. A AACE (American Association of Clinical Endocrinologists), bone mineral density recommendations of,
More informationDENOSUMAB (PROLIA & XGEVA )
DENOSUMAB (PROLIA & XGEVA ) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 306.3 T2 Effective Date: July 2, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationPrevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist
Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Prevalence of Osteoporosis 1.5 million fractures annually in the U.S. Overall lifetime risk for an osteoporotic fracture is about
More informationDrugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics
Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationOsteoporosis update. Dr. Claire Vandevelde Consultant Rheumatologist, LTHT
Osteoporosis update Dr. Claire Vandevelde Consultant Rheumatologist, LTHT Outline Background BMD Tools for assessing fracture risk Case study Denosumab Treatment breaks BMD BMD predicts fracture risk but
More informationPresenter: 翁家嫻 Venue date:
FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURES 1 Presenter: 翁家嫻 Venue date: 2018.03.13 PMO: postmenopausal osteoporosis. 1. Prolia (denosumab), Summary of Product
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationWhat is Osteoporosis?
What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of
More informationWhat Is FRAX & How Can I Use It?
What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical
More informationHAART HIV & BONE METABOLISM HAART EDITORIAL. Bologna, April 5 th, 2013
HIV correlated pathologies and other infections HIV & BONE METABOLISM Bologna, April 5 th, 2013 Morning Session: Davide Gibellini, Fabio Vescini, Paolo Bonfanti, Stefano Mora, Antonio Di Biagio, Tiziana
More informationManagement of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC
Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Learning Goals Review guidelines for osteoporosis Consider
More informationDisclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014
Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationIntroduction to osteoporosis. Editing file OBJECTIVES :
Introduction to osteoporosis OBJECTIVES : 1/ Understanding the definition of osteoporosis 2/ Causes of osteoporosis 3/ Impact of osteoporosis 4/ Diagnosis of osteoporosis 5/ Treatment of osteoporosis Editing
More informationOsteoporosis - New Guidelines. Michelle Glass B.Sc. (Pharm) June 15, 2011
Osteoporosis - New Guidelines Michelle Glass B.Sc. (Pharm) June 15, 2011 Outline What is Osteoporosis? Who is at risk? What treatments are available? Role of the Pharmacy technician Definition of Osteoporosis
More informationOklahoma Spine & Brain Institute is Proud to Introduce Michael Thambuswamy, MD, MBA
Oklahoma Spine & Brain Institute is Proud to Introduce Michael Thambuswamy, MD, MBA Michael Thambuswamy, M.D., is from the Tulsa area where he graduated, with honors, from Jenks High School. He completed
More informationPractical Management Of Osteoporosis
Practical Management Of Osteoporosis CONFERENCE 2012 Education Centre, Bournemouth.19 November The following companies have given funding towards the cost of this meeting but have no input into the agenda
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationEffects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis
Effects of Anti RANK ligand Denosumab on Beta Thalassemia induced osteoporosis Mohamed Yassin 1 Ashraf T. Soliman2, Mohamed O. Abdelrahman3, Vincenzo De Sanctis 4 Departments of, 1 Hematology 2Pediatric
More informationDISCLAIMER DO NOT DISTRIBUTE
DISCLAIMER The information contained in this presentation is not intended as a substitute for professional medical advice, diagnosis, or treatment. It is provided for educational purposes only. You assume
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationSubmission to the National Institute for Clinical Excellence on
Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationThe Risk Factors and Prevention of Osteoporosis
ISSN UA Volume 01 Issue 01 June-2018 The Risk Factors and Prevention of Osteoporosis Astha Vyas 1 and Ganga Sharma 1 Available online at: www.xournals.com Received 12 th December 2017 Revised 16 th February
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationEndocrine secretion cells secrete substances into the extracellular fluid
Animal Hormones Concept 30.1 Hormones Are Chemical Messengers Endocrine secretion cells secrete substances into the extracellular fluid Exocrine secretion cells secrete substances into a duct or a body
More informationRama Nada. - Mousa Al-Abbadi. 1 P a g e
- 1 - Rama Nada - - Mousa Al-Abbadi 1 P a g e Bones, Joints and Soft tissue tumors Before we start: the first 8 minutes was recalling to Dr.Mousa s duties, go over them in the slides. Wherever you see
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationdenosumab (Prolia ) Policy # Original Effective Date: 07/21/2011 Current Effective Date: 04/19/2017
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationBased on review of available data, the Company may consider the use of denosumab (Prolia) for the
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationNew Developments in Osteoporosis: Screening, Prevention and Treatment
Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationMusculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients
Musculoskeletal Clinical Correlates: Osseous Conditions in Dental Patients Learning Objectives Define osteoporosis and explain how it is diagnosed. Describe the main risk factors for developing osteoporosis.
More informationPrevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療
Prevention and Treatment of OSTEOPOROSIS 骨質疏鬆的預防與治療 Gwo Jaw Wang, M.D. 王國照教授 University of Virginia (U.S.A.) & National Cheng Kung University (Taiwan) Learning Objectives Pathophysiology of osteoporosis
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
: assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationOsteoporosis: Who, What, When, Why, and How
Osteoporosis: Who, What, When, Why, and How Doris J. Uh, PharmD, AE-C Pharm 445 September 20, 2005 Objectives define osteoporosis (what) determine high risk groups (who, when) review modifiable, non-modifiable
More information